Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE UC OLE: Etrasimod in Moderately to Severely Active Ulcerative Colitis
NCT03950232Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2019
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 39
01
Overview
A Phase 3 trial of etrasimod in ulcerative colitis (UC), sponsored by Pfizer. Started Sep 2019; status: active, not recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03950232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950232.